Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III outpatient study of AT-527 for mild to moderate COVID-19
2020-005759-18Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AT-527 with Placebo (2 arms). Primary endpoint: Time to alleviation or improvement of COVID-19 symptoms. Started Mar 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005759-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005759-18.